ArticleVaccines2025

Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial.

Haijing Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.